This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Juvenile Polyarteritis연소성 다발동맥염 (연소성다발동맥염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M30.2 | Special Copayment Reduction: V134 (rare disease Special Copayment Reduction)
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood low — by definition, juvenile polyarteritis is the pediatric form of polyarteritis nodosa with onset in childhood (mostly before age 15). New onset in adults is classified as adult polyarteritis nodosa (M30.0). However, cases that were mild and not diagnosed in childhood may first be diagnosed in early adulthood.
1. HistoryDistinguished as the pediatric form of polyarteritis nodosa. Sporadic descriptions of pediatric vasculitis cases since the 1860s → 2006, EULAR/PReS pediatric vasculitis classification criteria established.
2. CausesPediatric form of polyarteritis nodosa; association with MEFV variants higher than in adults (about 30–50%); low HBV association; mostly idiopathic.
3. GeneticsAssociated with heterozygous MEFV variants (M694V, etc.); genetic predisposition more prominent than in adult polyarteritis nodosa. ANCA-negative.
4. General epidemiology0.2–1 per million population per year (children); male predominance at 5–15 years; relatively frequent in ethnic groups with high frequency of MEFV variants.
5. PathophysiologyImmune complex- or T-cell-mediated necrotizing vasculitis of medium-sized vessels. With MEFV variants, abnormal pyrin function → excessive IL-1β secretion → neutrophil activation → vascular injury.
6. SymptomsFever and weight loss + skin nodules and livedo reticularis (more common than in adults) + myalgia + neuropathy + abdominal pain. Low HBV association in children.
7. SignsSubcutaneous nodules of the lower limbs and livedo reticularis, ANCA-negative, elevated ESR and CRP, renovascular hypertension, asymmetric peripheral nerve deficits, microaneurysms on angiography.
8. ScreeningVasculitis panel in children with the combination of unexplained fever + skin nodules + livedo reticularis + myalgia; MEFV gene testing; evaluation for renovascular hypertension.
9. Diagnosis2006 EULAR/PReS criteria: histology (fibrinoid necrotizing vasculitis) or angiographic abnormality + at least 1 of the 10 ACR criteria items + ANCA-negative.
10. TreatmentSteroids ± cyclophosphamide (severe). Mild (cutaneous form): steroids alone ± NSAIDs. Colchicine added when MEFV-associated. Pediatric pharmacokinetics considered.
11. PrognosisSystemic form: 5-year survival about 70–85%; cutaneous form: good. Major prognostic factors: renal, cardiac and intestinal involvement. Overall better prognosis than in adults.
12. PreventionNo primary prevention. Adjust treatment intensity after early diagnosis; minimize steroids; colchicine when MEFV-associated; treat streptococcal infection in the cutaneous form.
13. References10 major international journals and guidelines

1. History

Juvenile Polyarteritis is the childhood-onset form corresponding to adult polyarteritis nodosa; for a long time it was not recognized as an independent disease entity, but it began to be classified separately as pediatric rheumatology developed. Cases of vasculitis in children were reported sporadically from the late 19th century, but they were described together as the same disease as adult polyarteritis nodosa.

As the specialty of pediatric rheumatology became systematized in the mid-to-late 20th century, the need to distinguish pediatric vasculitis from adult vasculitis emerged. It was recognized that, unlike adult polyarteritis nodosa, skin involvement is more common in the pediatric form, the HBV association is low and certain clinical patterns differ. In addition, as an association with variants of the MEFV gene, which causes familial Mediterranean fever (FMF), was reported as particularly prominent in children, the independent character of juvenile polyarteritis drew attention.

At a joint meeting of the European League Against Rheumatism (EULAR) and the Paediatric Rheumatology European Society (PReS) held in Vienna, Austria in 2005, standardized nomenclature and classification criteria for pediatric vasculitis were proposed for the first time, and in the EULAR/PReS consensus criteria published in 2006, Juvenile Polyarteritis Nodosa was officially recognized as an independent category of pediatric vasculitis. These criteria modified the adult ACR 1990 criteria for children and require abnormal findings on tissue biopsy or angiography. In Korea, it is classified under ICD-10 code M30.2, and Special Copayment Reduction V134 applies.


2. Causes

As with adult polyarteritis nodosa, the cause of juvenile polyarteritis is mostly idiopathic, but in children, specific associations different from those in adults appear.

Strong association with MEFV gene variants: in juvenile polyarteritis, the frequency of heterozygous MEFV gene variants related to familial Mediterranean fever (FMF) is much higher than in adult polyarteritis nodosa. Although it differs by study, there are reports that MEFV variants (M694V, M680I, E148Q, etc.) are found in about 20–50% of patients with juvenile polyarteritis. This is interpreted to mean that heterozygous MEFV variants do not directly cause juvenile polyarteritis but act as susceptibility factors that amplify the vascular inflammatory response. In particular, MEFV variant testing should be considered when juvenile polyarteritis is diagnosed in children of Mediterranean ethnic origin.

HBV association: unlike adult polyarteritis nodosa, in which the proportion associated with HBV was high in the past, the HBV association in juvenile polyarteritis is markedly low. Now that HBV vaccination has become universal, HBV-related juvenile polyarteritis is very rare in children.

Other infection associations: cases of juvenile polyarteritis occurring after parvovirus B19 and streptococcal infections have been reported. In particular, some studies have suggested that streptococcal infection may trigger pediatric polyarteritis nodosa.

Idiopathic: idiopathic cases occurring without a clear cause still account for the majority, with medium-vessel inflammation arising from autoimmune mechanisms. ANCA negativity is a defining characteristic of juvenile polyarteritis.


3. Genetics

The genetics of juvenile polyarteritis shares some features with adult polyarteritis nodosa but is characterized by a more prominent association with the MEFV gene in children.

MEFV gene: heterozygous variants of the MEFV gene (16p13.3, encoding the pyrin protein), which causes familial Mediterranean fever, increase susceptibility to juvenile polyarteritis. Pyrin is an inflammasome-regulating protein, and with MEFV variants, excessive secretion of inflammatory cytokines including IL-1β occurs, which can amplify neutrophil overactivation and the vascular inflammatory response. Cases have been reported in which juvenile polyarteritis and FMF occur together or in which colchicine treatment is useful in patients with juvenile polyarteritis.

HLA associations: HLA-B51 (associated with Behçet disease), HLA-DR4 and others have been studied in pediatric vasculitis, but an HLA marker specific to juvenile polyarteritis has not yet been established.

ANCA negativity: as with adult polyarteritis nodosa, ANCA (MPO-ANCA, PR3-ANCA) negativity is part of the definition of juvenile polyarteritis. If ANCA is positive, it should be reclassified as ANCA-associated pediatric vasculitis (e.g., the pediatric form of microscopic polyangiitis).

Familial occurrence: most cases occur sporadically, but cases of juvenile polyarteritis occurring together in families sharing MEFV variants have rarely been reported.


4. General epidemiology

Juvenile polyarteritis is a very rare vasculitis occurring in children, with an estimated incidence of about 0.2–1 per million children per year. In European epidemiologic studies of pediatric vasculitis, the annual incidence is reported as about 0.4–0.9 per million children.

Age and sex distribution: the age of onset is most common in school-age children (5–15 years), and boys are slightly more affected than girls. Onset in infancy is rare. Unlike the predominance of middle-aged men in adult polyarteritis nodosa, the sex difference is less pronounced in children.

Geographic and ethnic distribution: it occurs in all ethnic groups worldwide, but it is reported to occur relatively more often in Mediterranean ethnic groups with a high frequency of MEFV variants (Turks, Armenians, Jews, Arabs). In a Turkish pediatric vasculitis cohort study, juvenile polyarteritis was reported at a higher frequency than in other countries.

Epidemiology in Korea: the number of patients with juvenile polyarteritis in Korea is extremely small, and the number registered under code M30.2 is estimated to be fewer than several dozen. It is managed as a rare case in pediatric rheumatology clinics, and Special Copayment Reduction V134 can be applied.

Cutaneous pediatric polyarteritis nodosa: cases of pediatric polyarteritis nodosa confined to the skin without systemic involvement (cutaneous juvenile PAN) are reported more commonly than the systemic form. The cutaneous form has a good prognosis, and a stronger association with streptococcal infection has been suggested.


5. Pathophysiology

The pathogenesis of juvenile polyarteritis basically shares the same pathologic mechanism as adult polyarteritis nodosa, but the association with MEFV gene variants suggests that the inflammasome activation pathway plays an important role in children.

Necrotizing vasculitis of medium-sized muscular arteries: transmural inflammation of medium-sized muscular arteries occurs through deposition of immune complexes in the vessel wall or a T-cell-mediated autoimmune response. Infiltration of the vessel wall by neutrophils, monocytes and lymphocytes → fibrinoid necrosis → microaneurysm formation → ischemic injury of downstream tissue is the main pathophysiology.

Inflammasome activation with MEFV variants: the normal pyrin protein acts as an inhibitory regulator of the NLRP3 inflammasome complex. When pyrin function is impaired by MEFV variants, the inflammasome becomes overactivated, increasing conversion of pro-IL-1β to active IL-1β. Excessively secreted IL-1β is a potent proinflammatory cytokine involved in neutrophil recruitment, endothelial cell activation and promotion of intravascular coagulation. The hypothesis that this abnormal activation of the pyrin-IL-1β axis contributes to the development and maintenance of vascular inflammation in juvenile polyarteritis is supported by reports of the therapeutic effect of colchicine.

Role of streptococcal antigens in pediatric cutaneous juvenile polyarteritis: in some cases of pediatric juvenile polyarteritis confined to the skin, a pattern of onset after streptococcal infection is observed. Streptococcal antigen-antibody immune complexes are presumed to deposit in cutaneous vessel walls, causing local vascular inflammation.

Distribution of vascular involvement and ischemic consequences: small and medium-sized arteries supplying the kidneys, skin, nerves and muscles are involved, and in children skin involvement (subcutaneous nodules, livedo reticularis, ulcers) tends to be more prominent than in adults.


6. Symptoms

The clinical symptoms of juvenile polyarteritis are similar to those of adult polyarteritis nodosa, but in children skin involvement tends to be more prominent and the frequency of visceral involvement somewhat different from adults.

Systemic symptoms: fever (persistent or intermittent), weight loss, fatigue and decreased appetite are common at onset. Growth delay may appear in children with chronic vasculitis.

Skin symptoms: one of the most common symptoms in juvenile polyarteritis. The proportion with skin involvement is reported to be higher than in adult polyarteritis nodosa. The main skin findings are as follows. Subcutaneous nodules: tender nodules forming on the lower limbs and along the course of arteries. Livedo reticularis: net-like violaceous skin discoloration. Ischemic skin ulcers. Purpura. Ischemia of the fingertips and toes.

Musculoskeletal symptoms: myalgia, especially lower limb myalgia, is common. Arthralgia or arthritis may occur, but joint destruction does not.

Neurologic symptoms: may be less frequent than in adults, but mononeuritis multiplex may occur. Headache and stroke due to cerebrovascular involvement also rarely occur.

Abdominal symptoms: mesenteric artery involvement can cause abdominal pain, nausea, diarrhea and bloody stools. In children, acute abdominal pain may be the first presentation, so differentiation from surgical conditions is needed.

Renal symptoms: renovascular hypertension may develop, and acute decline in renal function due to renal infarction also rarely occurs. Glomerulonephritis (hematuria, red cell casts) is a finding outside the definition of juvenile polyarteritis.

Cutaneous form (cutaneous juvenile PAN): a mild form confined to the skin without systemic symptoms, presenting with subcutaneous nodules, livedo reticularis and skin ulcers, often occurring after streptococcal infection.


7. Signs

The physical signs of juvenile polyarteritis vary with the organs involved and are similar to those of adult polyarteritis nodosa, but there are features specific to children.

Skin signs: tender subcutaneous nodules on the lower limbs and proximal areas and net-like livedo reticularis are characteristic. Ulcerative lesions develop after necrosis of nodules, and ischemic changes of the distal fingers and toes rarely appear.

Vital signs: fever is common. Renovascular hypertension also occurs in children and should be assessed using age-specific normal blood pressure standards for children.

Neurologic signs: asymmetric peripheral nerve deficits (mononeuritis multiplex). Asymmetric axonal injury pattern on nerve conduction studies.

Laboratory findings: markedly elevated ESR and CRP; leukocytosis; mild to moderate anemia; ANCA (MPO, PR3) negative — required; HBsAg negative in most; MEFV variant testing (when suspected); no glomerulonephritis findings on urinalysis (no hematuria or red cell casts).

Imaging findings: multiple microaneurysms and alternating stenosis and dilation of the renal, mesenteric and hepatic arteries on CTA or digital subtraction angiography (DSA) are characteristic. Abdominal angiography is a key diagnostic tool in children as well.

Histologic findings: fibrinoid necrotizing vasculitis of small and medium-sized arteries is confirmed on biopsy of subcutaneous nodules or skin.


8. Screening

There is no universal screening of the general pediatric population for juvenile polyarteritis. However, targeted evaluation for early diagnosis is important in children who present with specific clinical combinations.

Clinical suspicion criteria: when the following findings appear in a child, an evaluation for pediatric vasculitis, including juvenile polyarteritis, should be performed. Unexplained fever + skin nodules or livedo reticularis; lower limb myalgia + subcutaneous nodules; mononeuritis multiplex in a child (foot drop, hand weakness); renovascular hypertension in a child; abdominal pain + fever + cutaneous vasculitis findings.

Initial screening test items: complete blood count (CBC), ESR, CRP; urinalysis; serum creatinine, liver function; ANCA (MPO, PR3) — negativity is characteristic of juvenile polyarteritis; HBsAg, anti-HBc; antistreptococcal antibodies (ASO, anti-DNase B) — to differentiate the streptococcal infection-associated cutaneous form; MEFV gene testing (in Mediterranean ethnic groups or with a clinical FMF pattern); blood pressure measurement (applying pediatric age-specific normal ranges).

Imaging screening: when clinically suspected, abdominal ultrasound is used to screen for renal and abdominal vascular abnormalities, and abnormal findings are confirmed with CTA or MRA.


9. Diagnosis

The diagnosis of juvenile polyarteritis is based on the 2006 EULAR/PReS consensus criteria (Özen et al.). These criteria are a modification of the adult ACR 1990 criteria for children.

2006 EULAR/PReS diagnostic criteria: there must be findings of necrotizing vasculitis of small or medium-sized vessels on tissue biopsy or angiographic abnormalities (microaneurysms, stenosis, occlusion), accompanied by at least one of the following: ① skin involvement (livedo reticularis, subcutaneous nodules, superficial skin infarction), ② myalgia/muscle tenderness, ③ hypertension (≥95th percentile for age in children), ④ peripheral neuropathy, ⑤ renal involvement (proteinuria, hematuria — excluding glomerulonephritis findings).

Confirmation of ANCA negativity: MPO-ANCA and PR3-ANCA negativity is a required condition for the diagnosis of juvenile polyarteritis. If ANCA is positive, reclassification as ANCA-associated pediatric vasculitis is considered.

Vascular imaging: multiple microaneurysms and alternating stenosis and dilation of the renal, mesenteric and hepatic arteries on CTA or DSA are characteristic. In children, MRA is considered first to minimize radiation exposure.

Tissue biopsy: biopsy of skin nodules or the gastrocnemius muscle is the most accessible method. Confirmation of fibrinoid necrotizing vasculitis and polymorphonuclear leukocyte infiltration supports the diagnosis.

MEFV gene testing: MEFV gene variant testing is performed when FMF features such as recurrent fever and abdominal pain are present or in children of Mediterranean ethnic origin.


10. Treatment

Treatment of juvenile polyarteritis is based on the treatment principles for adult polyarteritis nodosa, but treatment intensity is adjusted in consideration of effects on children's growth and development, pharmacokinetic differences and a better prognosis than in adults.

Systemic form (major organ involvement): remission induction is started with high-dose glucocorticoids (prednisolone 1–2 mg/kg/day, maximum 60–80 mg/day). When there is severe organ involvement (renal failure, severe neuropathy, cardiac involvement), combination with cyclophosphamide is considered. Because steroid adverse effects (growth suppression, osteoporosis, Cushing syndrome) may be more serious in children than in adults, early tapering to the minimum effective dose is important. After remission is achieved, maintenance is continued by switching to azathioprine or methotrexate (pediatric indications must be confirmed).

Cutaneous form (cutaneous juvenile PAN): in the mild cutaneous form, symptoms are controlled with NSAIDs (aspirin, ibuprofen), and low-dose steroids are sometimes needed. When associated with streptococcal infection, antibiotic treatment (amoxicillin or penicillin) may help.

Treatment associated with MEFV variants: when a heterozygous MEFV variant is confirmed and FMF features (recurrent fever, peritonitis) are present, adding colchicine (weight-based dosing) may help. Colchicine inhibits inflammasome activation, reducing IL-1β secretion.

Management of vascular complications: renovascular hypertension is treated with ACE inhibitors or ARBs. When vascular complications such as aneurysm rupture or intestinal infarction occur, vascular intervention or surgery is needed.


11. Prognosis

The prognosis of juvenile polyarteritis is similar to that of adult polyarteritis nodosa but is reported to be somewhat better overall. However, when there is systemic involvement, serious morbidity and mortality can still occur.

Prognosis of the systemic form: the 5-year survival of systemic juvenile polyarteritis with major organ (kidney, heart, intestine) involvement is reported to be about 70–85%. Renal failure, cardiac involvement and intestinal infarction are the main causes of death. Early diagnosis and aggressive treatment are important for improving prognosis.

Prognosis of the cutaneous form: cutaneous juvenile polyarteritis confined to the skin without systemic involvement has a very good prognosis. It responds well to steroid treatment, and many patients maintain long-term remission or a near-cured state. However, progression to the systemic form has rarely been reported, so follow-up is needed.

Long-term complications: persistent hypertension, reduced renal function and sequelae of peripheral neuropathy cause long-term morbidity. Growth suppression in children, osteoporosis and increased fracture risk due to long-term steroid administration are important. The risk of reproductive impairment depending on the cumulative dose of cyclophosphamide is also a more sensitive issue in children.

Relapse: relapse is possible after treatment, and particular attention to relapse is needed during steroid tapering. In patients with MEFV variant association, colchicine treatment may help prevent relapse.


12. Prevention

There is no specific primary prevention for juvenile polyarteritis. Because treatment adverse effects can be more serious in children than in adults, it is important to maintain the minimum effective treatment intensity after early diagnosis.

Relapse prevention: to maintain remission after treatment, remission maintenance agents (azathioprine, methotrexate) are appropriately maintained, and steroids are not tapered too quickly. ESR, CRP, blood pressure and urinalysis are monitored regularly to detect relapse early.

Colchicine in MEFV-associated patients: in patients with a confirmed heterozygous MEFV variant, long-term colchicine administration may help prevent relapse.

Prevention of streptococcal infection in the cutaneous form: in cutaneous juvenile polyarteritis, when streptococcal infection acts as a trigger for relapse, long-term prophylactic antibiotics (low-dose penicillin V or amoxicillin) to prevent recurrent infection may be considered.

Minimizing steroid adverse effects: for children's growth and bone health, calcium and vitamin D supplementation, regular bone density assessment, maintenance of the minimum effective steroid dose and switching to alternate-day dosing are recommended.

Support for return to school and society: because pediatric patients with juvenile polyarteritis may have limited academic and social participation due to long-term treatment and complications, comprehensive management including a school return plan, psychological support and regular follow-up is needed.


13. References

  1. Özen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Ann Rheum Dis. 2010;69(5):798-806. DOI: 10.1136/ard.2009.116624. PMID: 20413568.

  2. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145(4):517-522. PMID: 15480376.

  3. Eleftheriou D, Brogan PA. Vasculitis in children. Best Pract Res Clin Rheumatol. 2009;23(3):309-323. DOI: 10.1016/j.berh.2009.01.003.

  4. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33(8):1088-1093. PMID: 2202309.

  5. Gedalia A, Cuchacovich R. Systemic vasculitis in childhood. Curr Rheumatol Rep. 2009;11(6):402-409. PMID: 19922729.

  6. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.

  7. Pagnoux C, Guillevin L. Peripheral neuropathy in systemic vasculitides. Curr Opin Rheumatol. 2005;17(1):41-48. PMID: 15604897.

  8. Eleftheriou D, Dillon MJ, Tullus K, et al. Systemic polyarteritis nodosa in the young: a single-centre experience over thirty-two years. Arthritis Rheum. 2013;65(9):2476-2485. DOI: 10.1002/art.38024.

  9. Brogan PA, Davies R, Gordon I, Dillon MJ. Renal angiography in children with polyarteritis nodosa. Pediatr Nephrol. 2002;17(4):277-283. PMID: 11956876.

  10. Hernández-Rodríguez J, Alba MA, Prieto-González S, Cid MC. Diagnosis and classification of polyarteritis nodosa. J Autoimmun. 2014;48-49:84-89.